| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Afsar, Rengin Elsurer |
|
| dc.creator |
Lentine, Krista L. |
|
| dc.date |
2024-06-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:40:50Z |
|
| dc.date.available |
2025-02-25T10:40:50Z |
|
| dc.identifier |
e9afb8e9-a179-4554-bfbd-06a09c38c155 |
|
| dc.identifier |
10.1007/s40200-024-01435-1 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/e9afb8e9-a179-4554-bfbd-06a09c38c155/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/101795 |
|
| dc.description |
Studies consistently showed that sodium-glucose cotransporter inhibitors (SGLTi) have cardiovascular and renal benefits, independent of their glucose lowering effects. Recent studies showed that SGLTi might influence gut microbiota. We performed a narrative review of publications focusing on use of SGLTi and changes in gut microbiota. Most studies showed that use of SGLTi re-shapes gut microbiota. These studies are heterogeneous regarding in study designs, doses and types of drugs used (SGLT1i vs. SGLT2i, or SGLT1/2i in combination) and the methods used to determine gut microbiota. However, existing data showed that SGLTi might alter food fermentation and gut permeability, which might translate into clinical outcomes. Thus the objective of this review is to summarize and discuss the updated data regarding SGLTi and changes in gut microbiota for the first time and suggest further study points that needs to be discovered. Graphical Abstract: (Figure presented.) |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review |
|
| dc.type |
info:eu-repo/semantics/article |
|